2026-01-28 - Analysis Report
**Company Overview**
Johnson & Johnson is a multinational healthcare and pharmaceutical company that develops, manufactures, and sells various medical devices, diagnostics, and consumer goods.

**Investment Performance Comparison**

* Ticker: JNJ
* Cumulative return: 80.57%
* Comparison stock (VOO): Cumulative return: 128.51%
* Degree of divergence (cumulative return difference): -47.94%

The cumulative return of JNJ is lower than the comparison stock VOO, which is a broad US stock market index. This indicates a divergence in investment performance between the two.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 9.0% | 16.9% | 0.0% | 0.7 | 310.9B |
| 2017-2019  | 21.0% | 16.9% | -4.0% | 0.7 | 351.4B |
| 2018-2020  | 13.0% | 25.9% | -11.0% | 0.7 | 379.2B |
| 2019-2021  | 26.0% | 25.9% | -38.0% | 0.6 | 412.2B |
| 2020-2022  | 15.0% | 25.9% | 11.0% | 0.5 | 425.6B |
| 2021-2023  | -11.0% | 14.1% | -29.0% | 0.3 | 377.6B |
| 2022-2024  | -23.0% | 14.1% | -52.0% | 0.2 | 348.4B |
| 2023-2025  | 37.0% | 14.1% | -38.0% | 0.1 | 498.6B |

The Alpha and Beta values indicate a relatively stable investment performance with a Beta of 0.4-0.9, suggesting a medium risk investment. However, the Alpha values show significant fluctuations, indicating a higher level of volatility.

**Recent Stock Price Fluctuations**

* Current price: $224.44
* 5-day SMA: $220.51
* 20-day SMA: $212.82
* 60-day SMA: $204.97

The stock price is above the 5-day and 20-day SMA, indicating a short-term upwards trend. However, the 60-day SMA is below the current price, indicating a longer-term downwards trend.

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence**

* Market Risk Indicator (MRI): 0.70
* RSI: 83.91
* PPO: 0.42
* Hybrid Signal: Buy
* Recent (20 days) relative divergence change: 1.80 (+)
* 7-day Rank change: -38 (-)
* 7-day Dynamic Expected Return change: -29.40 (-)

The RSI and PPO indicators suggest a high risk investment, as the RSI is above 80 and the PPO is above 0.4. However, the Market Risk Indicator and the recent relative divergence change indicate a medium risk investment.

**Expected Return**
-65.60%

The expected return is a negative value, indicating a potential loss of investment value.

**Recent News & Significant Events**

See the provided news headlines below:

* [2026-01-27] Pfizer vs. Merck Stock And JNJ - Forbes (news.google.com)
* [2026-01-27] JNJ Stock Rises On Fresh FDA Approval For Multiple Myeloma Drug - Stocktwits (news.google.com)
* [2026-01-22] How Two Rivals Undercut J&J's Beat And Big Guidance - Investor's Business Daily (news.google.com)
* [2026-01-27] Johnson & Johnson $JNJ Shares Purchased by Mn Services Vermogensbeheer B.V. - MarketBeat (news.google.com)
* [2026-01-27] JNJ Delivers Strong 2026 Guidance Even as Policy Costs Loom - Yahoo Finance (news.google.com)
* [2026-01-26] Johnson & Johnson Stock: 2026 Outlook After 50% Gains - TIKR.com (news.google.com)

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 225.34 / 265.00 / 155.00

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|----|----|--------|
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |
| 2025-10-22 | 1.12 | $22.47B |

The recent earnings analysis shows a fluctuating EPS and revenue value, with a high EPS value in Q4 2025.

**Financial Information - Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |

The revenue and profit margin values show a fluctuating trend, with a high profit margin in Q3 2025.

**Financial Information - Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |

The equity and ROE values show a fluctuating trend, with a high ROE value in Q3 2025.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.